摘要 |
This invention provides a multilamellar liposome containing an arachidonic acid metabolite, two or more lipid-containing bilayers and two or more aqueous compartments containing a release-inhibiting buffer. Preferred arachidonic acid metabolites are the prostaglandins, particularly PGE1. The liposomal formulations can be used to treat animals, particularly humans, for diseases, disorders or conditions which can be ameliorated by prostaglandins, e.g. disorders characterized by cellular activation and ahesion, inflammation and/or toxemia.
|
申请人 |
THE LIPOSOME COMPANY, INC. |
发明人 |
LENK, ROBERT, P.;TOMSHO, MICHELLE, L.;SUDDITH, ROBERT, L.;KLIMCHAK, ROBERT, J.;JANOFF, ANDREW, S.;MINCHEY, SHARMA, R.;OSTRO, MARC, J. |